Rare Disease - Infectious Disease/Oncology company specializing in the development of sabizabulin (microtubule disruptor) an investigational treatment in the hospitalized Covid-19/ARDS patient.• Third employee hired with remit to build the commercial plan and infrastructure of the Infectious Disease Franchise. • Supported the development and hiring of the organization’s first commercial sales team consisting of 40 hospital focused sales directors.• Hired, led, coached, and mentored 10 Hospital Institutional Directors across the Southeast area.• Partnered and worked closely with cross-functional teams including Marketing, Market Access, Sales Operations, Data Analytics, IC and Medical Affairs. • Worked directly with the top 300 hospitals across the Southeast and the Top 50 IDNs in the nation.

Rare Disease company specializing in the development of Tavalisse®, fostamatinib for treatment in the hospitalized Covid-19 patient. • Responsible for the hiring & management of 11 Hospital Sales Representatives across the Southeast area • Profiled the top 75 hospitals across the Southeast and conducted 15 meetings with large health systems and IDNs: AdventHealth-South Campus, AdventHealth-Waterman Campus, Orlando Health, Methodist Health System – Dallas, Huntsville Hospital, Piedmont Health System – Atlanta, and UAB during Q1/Q2 2022.

Start-up pharmaceutical company focused on the commercialization of the first and only 24-hour, once daily, non-opioid IV meloxicam on the market for the treatment of moderate to severe pre/post-surgical acute pain in Orthopedics surgery. • Supported the development and hiring of the organization’s first commercial sales team consisting of 50 Acute Care Specialists for the launch of Anjeso® into the Acute Care setting.• Utilized C-Suite and KOL relationships to gain hospital access during the pandemic. • Responsible for securing formulary wins at 35 Institutions, HOPD, ASC, during the COVID-19 pandemic.• Secured committed review/product monograph development at one of the largest IDNs in the US, AdventHealth (54 Institutions), and Orlando Health/Jewett Orthopedics (18 Institutions). • Established Volume Based Contracts and 340B pricing with largest institutions/IDNs from Miami to New England.• Ranked #1 in East Area for units sold/volume and #1 in total customers developed ordering with 80 accounts.• Led the first Area to exceed 1,000 and 2,000 units sold during year one.

Bio-pharmaceutical company focused on the commercialization and re-launch of brand assets within the pain and opioid induced constipation market.• Led, coached, and mentored the expansion Southeast Region sales team of 9 Pain Territory Managers. • Executed the commercialization re-launch of Belbuca® B.E.M.A technology for chronic pain, Bunavail® for opioid use disorder and Symproic® for opioid induced constipation.o 2018 – 2019 increased TRx growth by 282% from 890 Trx to 3,400 TRx (Q42019)o 2018 – 2019 increased unit (films) growth by 282% from 53,400 to 204,000 (Q42019)o 2018 – 2019 increased prescriber base 189% from 83 (January 2018) to 240 (December 2019) and an increase of 157 new prescribers.o 2018 – 2019 increased Humana prescriptions 1,345% from 47 (Q12018) to 679 (Q42019)• Implemented Direct-to-Patient pharmacy strategy with the largest specialty pharmacy in the US to assist with the Prior Authorization process and patient access in the Southeast. • Developed advocacy group strategy through “Project Opioid” with the Central Florida Opioid Task Force and Florida Blue to improve patient access.

Start-up commercial pharmaceutical company focused on the development of low dose NSAID compounds utilizing a proprietary technology, SoluMatrix Fine Particle®. • Supported the development and hiring of the organization’s first commercial sales team consisting of 300 sales representatives for the effective launch of Zorvolex® • Developed, led, and implemented the sales strategy for 9 sales professionals throughout the Southeast US. Customer base and relationships within Orthopedics, Pain, Neurology, Rheumatology, and Primary Care. • Implemented Direct to Patient pharmacy strategy throughout the State of Florida to assist with the obstacles of Step Edits and Prior Authorizations. Ranked #1 in the Nation and SE Area in Total Rx (141%) and NRx (112%) growth during Q4 2014. Region generated more than 3,300 prescriptions during launch year in a highly genericized marketplace. • 2017 Ranked #1 in TRx Growth - Portfolio, Vivlodex® & Zorvolex®• 2016 Ranked #1 in TRx Growth – Portfolio & TRx, Volume - Vivlodex®. AWARDS: 2017 Area Director Chairman’s Club

Healthcare consulting firm with emphasis in acquiring commercial assets for a fully integrated Fortune 500 US based pharmaceutical organization. -Signed contractual consulting agreement consisted of full commercial due diligence on FDA approved assets and acquisition opportunities. -Worked on four products within the pediatric, pain, dermatologic, neurology and injectable space in 2012 & 2013.

Established generic pharmaceutical focused on the build out of their first brand commercial team. • Led the commercial and sales force development in the Eastern US for MoxDuo® (2012) the flagship pain management drug (Projected sales of $300MM and an operating budget of $30MM). • Develop and commercial implementation of brand strategies, sales force strategy and deployment, targeting, IC, forecasting, trade strategy, pricing, and market research. • Led team of sales and key account representatives (77), and regional business directors (8).AWARDS: 2012 Area Director of the Year Award – Greatest increase in overall business AND 2011 Achievement through Excellence of the Year Award

• Led the commercial sales and strategy development plan for the Kadian® brand team consisting of 14 sales specialists in the Gulf Coast Region. o Responsible for staffing and hiring (including two expansions), quota setting, incentive compensation plan, forecasting and strategic planning/development resulting in +$270M. o Revenues for business unit increased $40MM or 17% from 2009 to 2011. • Developed sales strategy, sales force alignment/targeting plan and IC plan for Oxymorphone business unit. Prescription’s average 7,000 per month (2011-2013).AWARDS: 2011 Achievement through Excellence of the Year Award

Start-up Bio-pharmaceutical company focused on the development of therapies that restore function and improve the lives of people with neurological disorders. • Led all sales activities including strategic/tactical planning, training, customer targeting and employee development for lead product Zanaflex® within the primary care, pain, and neurology markets.o Instrumental in the strategy for the first internally developed commercial product.• Committee Chair for developing strategic plans to align market targets, sales objectives, compensation models and marketing plans to align with the overall corporate goals.• Achieved sales results of $25MM with area business managers (12) in Southeast US Region. • Co-developed telesales projects designed to target business opportunities not included in the sales force targeting plan resulting in expanding projected growth projections.AWARDS: 2008 Trailblazer – Founding member of commercial arm and 2007 Peer Recognition of the Year

Start-up Bio-pharmaceutical company developing therapies that target MRSA pathogens. • Responsibilities included all sales activities for Cubicin® to hospitals throughout the Southeast. • Developed a national outpatient “buy and bill” strategy for the infectious disease market. • Assisted in development of J-code billing approval process for national roll-out.• Developed and facilitated initial SE physician/hospital advisory board meetings in Orlando, FL • Developed contract strategy to secure the first and largest regional hospital system in the nation—including 24 hospitals in the Southeast US. AWARDS: 2004 National Clinical Business Manager of the Year, 2004 National MVP of the Year and 2004 Peer Recognition Award

Start-up Bio-pharmaceutical company specializing in the develop of drugs for HIV wasting disease and the treatment of resistant chronic gout.• Responsible for developing and implementing strategic business plan to meet corporate goals. • Managed 13 area managers with sales results of $19MM (2001) and $31MM (2002). • Member of the initial leadership team responsible for the commercial team build. • Co-developed product sales training department. AWARDS: 2002 #1 in Overall Sales, President’s Club - Southeast Business Unit and 2001 National Area Manager of the Year, President’s Club

Responsible for the promotion of Bio-pharmaceuticals to Infectious Disease specialist, Oncologist and Wound Care physicians and hospitals throughout Central and North Florida. Developed new business ventures, for the company, within Florida Department of Health and Florida Department of Corrections. Instituted statewide formulary approvals at both organizations, which directly increased sales $1.7 million in two years. Coordinated efforts between sales/marketing and clinical to secure preferred formulary status with Florida Medicaid for four years. Increased sales from $700,000 in 1998 to 2.3 million in 2000. Increased market share from 18.3% in 1998 to 57.7% in 2000.

Responsible for acquiring physicians and group practices throughout the Eastern US. Duties included selling and managing acquisition and MSO models to better assist physician groups in competing with managed care through fee for service, capitated and global risk contracting. Organized a Full Service Diagnostic Center and a Primary Care IPA network throughout Central Florida that consists of 30+ physicians. Developed a Management Services Organization that consists of 9 physician groups with revenues in excess of $18 million.